Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Nicholls

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|January 17, 2012
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathySandro Feriozzi, Joan Torras, Markus Cybulla, et al.
Nephrology (Carlton, Vic.)|December 24, 2010
Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipientsNigel D Toussaint, Marcus B P Tan, Kathy Nicholls, et al.
Journal of Nephrology|October 2, 2012
Kidney transplantation and enzyme replacement therapy in patients with Fabry diseaseMarkus Cybulla, Christine Kurschat, Michael West, et al.
Palliative Medicine|August 23, 2005
Renal dialysis abatement: lessons from a social studyMichael Ashby, Corinne op't Hoog, Allan Kellehear, et al.
JIMD Reports|February 23, 2013
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceJoanna Ghali, Kathy Nicholls, Charles Denaro, et al.
Ophthalmic Genetics|August 4, 2016
Bull's eye and pigment maculopathy are further retinal manifestations of an abnormal Bruch's membrane in Alport syndromeJudy Savige, Yanyan Wang, Andrew Crawford, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|December 13, 2006
Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiencyAnil K Agarwal, Xin J Zhou, Roger K Hall, et al.
Molecular Genetics and Metabolism Reports|December 22, 2021
Corrigendum to "Long-term follow-up of renal function in patients treated with migalastat for Fabry disease" [Bichet et al., MGM Reports; 28 (2021) 100786]Daniel G Bichet, Roser Torra, Eric Wallace, et al.
Molecular Genetics and Metabolism Reports|August 17, 2021
Long-term follow-up of renal function in patients treated with migalastat for Fabry diseaseDaniel G Bichet, Roser Torra, Eric Wallace, et al.
Drug Design, Development and Therapy|November 22, 2019
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) AnalysisUma Ramaswami, Michael Beck, Derralynn Hughes, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Clinical Journal of the American Society of Nephrology : CJASN|January 17, 2012
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathySandro Feriozzi, Joan Torras, Markus Cybulla, et al.
Nephrology (Carlton, Vic.)|December 24, 2010
Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipientsNigel D Toussaint, Marcus B P Tan, Kathy Nicholls, et al.
Journal of Nephrology|October 2, 2012
Kidney transplantation and enzyme replacement therapy in patients with Fabry diseaseMarkus Cybulla, Christine Kurschat, Michael West, et al.
Palliative Medicine|August 23, 2005
Renal dialysis abatement: lessons from a social studyMichael Ashby, Corinne op't Hoog, Allan Kellehear, et al.
JIMD Reports|February 23, 2013
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceJoanna Ghali, Kathy Nicholls, Charles Denaro, et al.
Ophthalmic Genetics|August 4, 2016
Bull's eye and pigment maculopathy are further retinal manifestations of an abnormal Bruch's membrane in Alport syndromeJudy Savige, Yanyan Wang, Andrew Crawford, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|December 13, 2006
Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiencyAnil K Agarwal, Xin J Zhou, Roger K Hall, et al.
Molecular Genetics and Metabolism Reports|December 22, 2021
Corrigendum to "Long-term follow-up of renal function in patients treated with migalastat for Fabry disease" [Bichet et al., MGM Reports; 28 (2021) 100786]Daniel G Bichet, Roser Torra, Eric Wallace, et al.
Molecular Genetics and Metabolism Reports|August 17, 2021
Long-term follow-up of renal function in patients treated with migalastat for Fabry diseaseDaniel G Bichet, Roser Torra, Eric Wallace, et al.
Drug Design, Development and Therapy|November 22, 2019
Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) AnalysisUma Ramaswami, Michael Beck, Derralynn Hughes, et al.
Pageof 4